In 2006, an estimated 530,000 children under age 15 worldwide were newly infected with HIV. An estimated 2.3 million children under age 15 are living with HIV, and 2 million of those children live in sub-Saharan Africa. A renewed commitment to effective antiretroviral treatment (ART) of HIV infection in children is essential; without treatment, the majority of infected children die before they are three years of age.
This partnership researches and develops new medicines and/or new formulations of existing medicines to treat children with HIV/AIDS, especially in developing countries in sub-Saharan Africa and Asia. In some cases, partners have signed licensing, patent and/or technology transfer agreements with generic drug manufacturers in South Africa, India and Brazil to make existing HIV/AIDS medicines available in developing countries at lower costs.
|Location||Eastern Africa, Angola, Zimbabwe, Zambia, Uganda, Togo, Tanzania, Swaziland, Sudan, Southern Sudan, South Africa, Somalia, Sierra Leone, Seychelles, Senegal, Sao Tome and Principe, Rwanda, Nigeria, Niger, Namibia, Mozambique, Mauritius, Mauritania, Mali, Malawi, Madagascar, Liberia, Lesotho, Kenya, India, Guinea-Bissau, Guinea, Ghana, Gambia, Gabon, Ethiopia, Eritrea, Equatorial Guinea, Cote d Ivoire, Congo, The Republic of, Congo, The Democratic Republic of, Comoros, Chad, Central African Republic, Cape Verde, Cameroon, Burundi, Burkina Faso, Botswana, Benin|